Obermatt
See Similar Stocks →

Flags

Earnings warning

Insmed

NSQ:INSM · US4576693075
BiotechnologyMedium

360

51
Profit price64
Owner Earnings Yield1
Dividend Yield1
Price/Sales26
EV / Gross Profit12
Price/Book1
Return on Capital12
Cash Return on Capital4
Return on Equity4
EBIT Margin7
Gross Profitability65
Accruals83
Owner Earnings Margin21
Sales growth90
Profit Growth1
Long-Term EPS Growth84
Reinvestment38
Price momentum59
Debt load23
Refinancing66
Debt Payback1
Liquidity29
Analyst ratings67
Opinion Changes71
Price Target Upside96
Market mood100
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Insmed doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded1999
Employees1,511
Websiteinsmed.com
ISINUS4576693075
Last UpdateApr 2, 2026
Indices
NASDAQ 100 (USA)NASDAQ (USA)D.J. US Health Care
Themes
Chronic DiseasesStem Cell TherapyImmunologyGeneticsInflammationPulmonologyRespiratoryBiotechnologyMedicalPharmaceutical

Description

Insmed Incorporated, a global biopharmaceutical company, delivers therapies to transform the lives of patients facing serious diseases. The company’s commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respirator…

Analysis

Middle-of-the-road

Insmed Incorporated sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is solid; the safety picture is adequate. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
30
2026

All-time high

43

Mar 2026

All-time low

30

Jun 2026

Average rank

37

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
26
—
—
—
Price/Earnings
97
—
—
—
Price/Book
1
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
23
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Insmed with its peers
Ligand Pharmaceuticals
NMQ:LGND
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
MBX Biosciences
NSQ:MBX
30
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
ACADIA Pharmaceuticals
NSQ:ACAD
80
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Neumora Therapeutics
NSQ:NMRA
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Nektar
NAQ:NKTR
4
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →